Orchid Pharma Ltd

Orchid Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Orchid Pharma Ltd

₹ 1,032 3.66%
08 May 4:01 p.m.
orchidpharma.com BSE: 524372 NSE : ORCHPHARMA
About

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]

Key Points

Product Portfolio
The Co has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products. Its Product portfolio constitute of API - Cephalosporins - Orals, Cephalosporins - Injectables, Veterinary Products & Non-Antibiotics. [1][2]

Website BSE NSE
  • Market Cap ₹ 5,243 Cr.
  • Current Price ₹ 1,032
  • High / Low ₹ 1,360 / 391
  • Stock P/E 59.4
  • Book Value ₹ 227
  • Dividend Yield 0.00 %
  • ROCE 4.79 %
  • ROE 2.01 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 4.54 times its book value
  • The company has delivered a poor sales growth of 0.67% over past five years.
  • Company has a low return on equity of -5.14% over last 3 years.
  • Earnings include an other income of Rs.57.4 Cr.
  • Promoter holding has decreased over last 3 years: -28.2%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
103 120 96 122 159 180 131 165 160 210 183 199 221
108 118 94 114 143 151 119 147 146 170 161 175 185
Operating Profit -6 2 2 7 16 29 12 18 14 40 22 24 36
OPM % -5% 2% 2% 6% 10% 16% 10% 11% 9% 19% 12% 12% 16%
2 3 3 54 2 -0 3 6 9 40 2 8 7
Interest 13 12 11 10 7 4 8 9 8 7 6 4 4
Depreciation 29 20 20 20 20 27 22 18 8 7 8 8 9
Profit before tax -45 -27 -26 32 -9 -2 -14 -3 7 65 11 20 31
Tax % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-45 -27 -26 32 -9 -2 -14 -3 7 65 11 20 31
EPS in Rs -11.11 -6.67 -6.37 7.84 -2.20 -0.44 -3.45 -0.81 1.65 15.89 2.13 3.99 6.02
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
1,663 1,736 1,907 1,736 879 755 644 584 481 451 557 666 812
1,335 1,375 1,767 1,416 705 740 622 590 531 413 498 581 691
Operating Profit 328 362 140 320 174 15 22 -6 -50 38 59 84 121
OPM % 20% 21% 7% 18% 20% 2% 3% -1% -10% 8% 11% 13% 15%
90 46 81 156 -28 -59 20 42 24 6 57 57 57
Interest 116 179 520 537 294 347 310 7 6 52 33 33 20
Depreciation 128 149 244 321 143 146 133 130 118 109 87 55 32
Profit before tax 174 80 -544 -383 -292 -537 -401 -101 -150 -117 -5 54 126
Tax % 8% -29% 2% 50% 6% 9% 12% 0% 0% 0% 0% 0%
159 103 -530 -191 -274 -489 -355 -101 -150 -117 -5 54 126
EPS in Rs 22.64 14.64 -75.26 -22.41 -30.83 -54.91 -39.94 -11.36 -36.71 -28.70 -1.18 13.28 28.03
Dividend Payout % 13% 20% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 1%
3 Years: 11%
TTM: 28%
Compounded Profit Growth
10 Years: %
5 Years: 15%
3 Years: 28%
TTM: 938%
Stock Price CAGR
10 Years: 34%
5 Years: 200%
3 Years: -13%
1 Year: 159%
Return on Equity
10 Years: %
5 Years: %
3 Years: -5%
Last Year: 2%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 70 70 70 85 89 89 89 89 41 41 41 41 51
Reserves 1,064 1,076 418 354 82 -432 -763 -844 757 641 637 691 1,103
2,069 1,996 3,204 3,211 3,214 3,106 3,202 3,230 566 453 268 331 325
686 756 1,031 506 577 595 683 518 86 90 148 160 13
Total Liabilities 3,888 3,899 4,723 4,156 3,963 3,358 3,211 2,993 1,450 1,224 1,094 1,223 1,491
1,596 1,931 2,483 1,697 1,540 1,402 1,291 1,161 858 670 584 573 564
CWIP 330 350 360 282 280 288 272 278 26 7 10 46 61
Investments 130 149 124 125 125 125 125 0 0 15 49 50 69
1,832 1,468 1,756 2,053 2,017 1,543 1,523 1,553 566 531 452 554 797
Total Assets 3,888 3,899 4,723 4,156 3,963 3,358 3,211 2,993 1,450 1,224 1,094 1,223 1,491

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
312 764 175 -370 211 402 6 15 80 24 90 13
-362 -309 -998 1,334 -1 -176 -28 45 167 67 113 -27
-73 -478 676 -597 -287 -465 33 -0 -250 -165 -217 31
Net Cash Flow -123 -24 -147 367 -76 -239 11 60 -3 -73 -14 18

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 106 19 35 61 156 101 82 88 50 107 105 116
Inventory Days 269 290 190 113 183 196 204 219 257 240 201 217
Days Payable 121 188 214 138 307 410 361 354 110 109 140 130
Cash Conversion Cycle 253 121 12 36 32 -113 -74 -47 197 237 165 204
Working Capital Days 196 38 -99 104 136 -214 -508 -724 197 332 160 179
ROCE % 9% 8% -2% 1% 2% -3% -3% -5% -7% -5% -2% 5%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
90.00% 90.00% 90.00% 90.00% 89.96% 89.96% 89.96% 89.96% 72.40% 72.40% 69.84% 69.84%
1.82% 1.79% 1.78% 1.61% 1.48% 1.37% 0.86% 0.81% 8.58% 8.08% 4.14% 1.96%
3.67% 3.35% 3.35% 2.97% 2.97% 2.98% 3.94% 2.62% 13.48% 12.46% 14.51% 17.73%
0.00% 0.04% 0.04% 0.04% 0.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
4.51% 4.83% 4.84% 5.39% 5.55% 5.69% 5.22% 6.60% 5.54% 7.05% 11.52% 10.47%
No. of Shareholders 33,37934,79833,53333,69833,67932,71730,89429,52329,13229,19736,93136,720

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls